A Study to Evaluate the Efficacy and Safety of AD-224
ConditionHypertension,Essential
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age19+
SponsorAddpharma Inc.
About this trial
The purpose of this study is to evaluate the efficacy and safety of AD-224
Eligibility criteria
Qualifiers
Signed informed consent
Patients with Essential Hypertension
Other inclusions applied
Disqualifiers
Patient with Secondary Hypertension
Other exclusions applied
Trial design
Treatments tested in this trial
- AD-224A
- AD-224B
- AD-224C
- Placebo of AD-224A
- Placebo of AD-224B
- Placebo of AD-224C
Treatment groups
252 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov